» Articles » PMID: 31302785

Health Sequelae of Human Cryptosporidiosis-a 12-month Prospective Follow-up Study

Overview
Publisher Springer
Date 2019 Jul 15
PMID 31302785
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

To investigate long-term health sequelae of cryptosporidiosis, with especial reference to post-infectious irritable bowel syndrome (PI-IBS). A prospective cohort study was carried out. All patients with laboratory-confirmed, genotyped cryptosporidiosis in Wales, UK, aged between 6 months and 45 years of age, over a 2-year period were contacted. Five hundred and five patients agreed to participate and were asked to complete questionnaires (paper or online) at baseline, 3 and 12 months after diagnosis. The presence/absence of IBS was established using the Rome III criteria for different age groups. Two hundred and five of 505 cases completed questionnaires (40% response rate). At 12 months, over a third of cases reported persistent abdominal pain and diarrhoea, 28% reported joint pain and 26% reported fatigue. At both 3 and 12 months, the proportion reporting fatigue and abdominal pain after Cryptosporidium hominis infection was statistically significantly greater than after C. parvum. Overall, 10% of cases had sufficient symptoms to meet IBS diagnostic criteria. A further 27% met all criteria except 6 months' duration and another 23% had several features of IBS but did not fulfil strict Rome III criteria. There was no significant difference between C. parvum and C. hominis infection with regard to PI-IBS. Post-infectious gastrointestinal dysfunction and fatigue were commonly reported after cryptosporidiosis. Fatigue and abdominal pain were significantly more common after C. hominis compared to C. parvum infection. Around 10% of people had symptoms meriting a formal diagnosis of IBS following cryptosporidiosis. Using age-specific Rome III criteria, children as well as adults were shown to be affected.

Citing Articles

Long-term symptoms in children after a Cryptosporidium hominis outbreak in Sweden: a 10-year follow-up.

Boks M, Lilja M, Lindam A, Widerstrom M, Persson A, Karling P Parasitol Res. 2025; 124(1):13.

PMID: 39862254 PMC: 11762772. DOI: 10.1007/s00436-025-08455-7.


Application of Silver Nanoparticles in Parasite Treatment.

Zhang P, Gong J, Jiang Y, Long Y, Lei W, Gao X Pharmaceutics. 2023; 15(7).

PMID: 37513969 PMC: 10384186. DOI: 10.3390/pharmaceutics15071783.


Persisting symptoms after Cryptosporidium hominis outbreak: a 10-year follow-up from Östersund, Sweden.

Boks M, Lilja M, Widerstrom M, Karling P, Lindam A, Sjostrom M Parasitol Res. 2023; 122(7):1631-1639.

PMID: 37199767 PMC: 10193336. DOI: 10.1007/s00436-023-07866-8.


Apoptotic changes in the intestinal epithelium of -infected mice after silver nanoparticles treatment versus nitazoxanide.

Hassan Z, Salama D, Ibrahim H J Parasit Dis. 2022; 46(4):1011-1020.

PMID: 36457780 PMC: 9606195. DOI: 10.1007/s12639-022-01520-3.


Gut Non-Bacterial Microbiota: Emerging Link to Irritable Bowel Syndrome.

Liu A, Gao W, Zhu Y, Hou X, Chu H Toxins (Basel). 2022; 14(9).

PMID: 36136534 PMC: 9503233. DOI: 10.3390/toxins14090596.


References
1.
Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K . British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome. Gut. 2000; 47 Suppl 2:ii1-19. PMC: 1766762. DOI: 10.1136/gut.47.suppl_2.ii1. View

2.
Hunter P, Nichols G . Epidemiology and clinical features of Cryptosporidium infection in immunocompromised patients. Clin Microbiol Rev. 2002; 15(1):145-54. PMC: 118064. DOI: 10.1128/CMR.15.1.145-154.2002. View

3.
Sing A, Bechtold S, Heesemann J, Belohradsky B, Schmidt H . Reactive arthritis associated with prolonged cryptosporidial infection. J Infect. 2003; 47(2):181-4. DOI: 10.1016/s0163-4453(03)00035-5. View

4.
Hunter P, Hughes S, Woodhouse S, Raj N, Syed Q, Chalmers R . Health sequelae of human cryptosporidiosis in immunocompetent patients. Clin Infect Dis. 2004; 39(4):504-10. DOI: 10.1086/422649. View

5.
Parry S, Forgacs I . Intestinal infection and irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2005; 17(1):5-9. DOI: 10.1097/00042737-200501000-00002. View